Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), collectively referred to as photocarcinomas, represent the most common forms of non-melanoma skin cancer, primarily caused by chronic ultraviolet (UV) radiation exposure. In advanced stages, whether locally invasive, recurrent, or metastatic, these tumors pose substantial therapeutic challenges, particularly among high risk populations such as the elderly, immunocompromised patients, and individuals with genetic susceptibility. For resectable disease, Mohs micrographic surgery remains the gold standard, achieving recurrence rates as low as 0.6%, alongside wide local excision as a standard surgical approach. In cases where surgery is not feasible, systemic therapies play a crucial role. Hedgehog pathway inhibitors demonstrate response rates of 56% in advanced BCC, while PD-1 inhibitors show efficacy of 50% in advanced SCC, approximately. The innovative strategies played a significant role in reshaping the therapeutic landscape. The advanced neoadjuvant treatments, nanotechnology-based drug delivery systems, and photodynamic therapy (PDT) are being developed to overcome drug resistance. The situation also communicates an instant retrieval of patients from the cancer. The personalized systems exploiting genomic outlining and AI-driven methods challenge molecular struggle and methodological restrictions. This inclusive method focuses on the developing scenery of photocarcinoma managing, accenting on personalized action strategies to equilibrium oncologic efficiency, purposeful conservation, and patient-centered overhaul for enhanced consequences in multifaceted situations.